TY - JOUR
T1 - Research Progress on Neuroprotection of Insulin-Like Growth Factor-1 towards Glutamate-Induced Neurotoxicity
AU - Ge, Lijun
AU - Liu, Shuyuan
AU - Rubin, Limor
AU - Lazarovici, Philip
AU - Zheng, Wenhua
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Insulin-like growth factor-1 (IGF-1) and its binding proteins and receptors are widely expressed in the central nervous system (CNS), proposing IGF-1-induced neurotrophic actions in normal growth, development, and maintenance. However, while there is convincing evidence that the IGF-1 system has specific endocrine roles in the CNS, the concept is emerging that IGF-I might be also important in disorders such as ischemic stroke, brain trauma, Alzheimer’s disease, epilepsy, etc., by inducing neuroprotective effects towards glutamate-mediated excitotoxic signaling path-ways. Research in rodent models has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 was administered by different routes, and several clinical studies have shown safety and promise of efficacy in neurological disorders of the CNS. Focusing on the relationship between IGF-1-induced neuroprotection and glutamate-induced excitatory neurotoxicity, this review addresses the research progress in the field, intending to provide a rationale for using IGF-I clinically to confer neuroprotective therapy towards neurological diseases with glutamate ex-citotoxicity as a common pathological pathway.
AB - Insulin-like growth factor-1 (IGF-1) and its binding proteins and receptors are widely expressed in the central nervous system (CNS), proposing IGF-1-induced neurotrophic actions in normal growth, development, and maintenance. However, while there is convincing evidence that the IGF-1 system has specific endocrine roles in the CNS, the concept is emerging that IGF-I might be also important in disorders such as ischemic stroke, brain trauma, Alzheimer’s disease, epilepsy, etc., by inducing neuroprotective effects towards glutamate-mediated excitotoxic signaling path-ways. Research in rodent models has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 was administered by different routes, and several clinical studies have shown safety and promise of efficacy in neurological disorders of the CNS. Focusing on the relationship between IGF-1-induced neuroprotection and glutamate-induced excitatory neurotoxicity, this review addresses the research progress in the field, intending to provide a rationale for using IGF-I clinically to confer neuroprotective therapy towards neurological diseases with glutamate ex-citotoxicity as a common pathological pathway.
KW - Animal models
KW - Clinical trials
KW - Glutamate-mediated excitotoxicity
KW - Insulin-like growth factor-1
KW - Neuroprotection
KW - Signaling pathways
UR - http://www.scopus.com/inward/record.url?scp=85124424026&partnerID=8YFLogxK
U2 - 10.3390/cells11040666
DO - 10.3390/cells11040666
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35203315
AN - SCOPUS:85124424026
SN - 2073-4409
VL - 11
JO - Cells
JF - Cells
IS - 4
M1 - 666
ER -